Introduction: Post-menopausal women with osteoporosis > 70 years of age at high risk of fracture urgently require treatment for fracture prevention. Moreover, persistence with osteoporosis therapy is critical for real-world effectiveness. We estimated persistence with denosumab in older women at high fracture risk in clinical practice in Bulgaria.
Methods: Eligible participants were post-menopausal women, > 70 years of age, diagnosed with osteoporosis (T-score ≤ - 2.5) and at high risk of fracture (≥ 3% for hip and ≥ 20% for major osteoporotic fracture) who received at least one denosumab injection before enrollment. Planned follow-up was 24 months. The primary endpoint was persistence to denosumab at 12, 18, and 24 months (defined as receiving all denosumab injections within 6 months ± 60 days of the previous injection).
Results: 250 women were enrolled across 12 Bulgarian endocrinology/rheumatology practices; median follow up, 736 days. Mean (SD) age was 75.8 (4.2) years; mean (SD) FRAX was 13.1 (8.6) for hip and 26.1 (9.5) for major osteoporotic fracture; 47 (18.8%) women had prior osteoporosis therapy and 104 (41.6%) had prior fracture. Denosumab persistence was high: 98.0%, 92.4%, and 84.4% at 12, 18, and 24 months, respectively. A total of 42 (16.8%) women discontinued denosumab during follow-up, mostly for financial reasons [25/42 (59.5%)] or loss to follow-up [8/42 (19.0%)]. After 24 months of denosumab treatment, BMD T-score improvement to the range of osteopenia (- 2.5 ≤ T < - 1.5) was achieved by 42.4% at the femoral neck, 23.6% at the lumbar spine, and 49.2% at the total hip; complete recovery (T-score ≥ - 1.5) was observed in 9.0%, 26.4%, and 23.0% respectively. New fracture was reported in 5 patients (2%).
Conclusions: Even in an elderly population, persistence with denosumab was high despite the challenge imposed by the 50% co-pay in Bulgaria.
Trial Registration: Bulgarian Drug Agency, №HИП-0009 (registered 28.06.2017); Central Ethics Commission: №КИ-41 (registered 16.05.2017).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990988 | PMC |
| http://dx.doi.org/10.1007/s40744-021-00282-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Giant cell tumor of the cervical spine: A case report.
Int J Surg Case Rep
January 2025
Orthopedic Surgery Department at Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Introduction: A Giant Cell Tumor (GCT) of the bone is a locally osteolytic tumor made up of mononuclear ovoid stromal cells and multinucleated giant cells. It commonly affects long bones like the distal femur and proximal tibia, but can also develop in the cervical spine during the third and fourth decades of life.
Presentation Of Case: A 20-year-old female presented to the clinic with a complaint of neck pain persisting for one month.
Pregnancy- and Lactation-Associated Osteoporosis: A Literature Review Based on a Clinical Case.
Cureus
November 2024
Orthopedics and Traumatology, Santo António University Hospital Center, Porto, PRT.
Article Synopsis
- Pregnancy- and lactation-associated osteoporosis (PLO) is a rare condition impacting women postpartum, exemplified by a case of a 29-year-old with severe back pain due to vertebral fractures.
- Diagnosis involves ruling out other causes of osteoporosis, with treatment typically including calcium and vitamin D supplements alongside lactation suppression; however, pain may persist even after treatment.
- The condition remains poorly understood, with potential causes including genetic factors and calcium metabolism changes, highlighting the need for early diagnosis and personalized treatment strategies for better patient outcomes.
Parathyroid Carcinoma Complicated by Parathyromatosis and Refractory Hypercalcemia.
Cureus
October 2024
Department of Endocrinology Diabetes Medicine, Samatvam Diabetes Endocrinology and Medical Center Samatvam: Science and Research for Human Welfare Trust, Bangalore, IND.
Parathyroid carcinoma (PC) is a rare malignancy. In January 2022, a 41-year-old woman presented with weight loss, proximal muscle weakness, and bone pain. She was diagnosed with severe hypercalcemia with serum calcium of 15.
View Article and Find Full Text PDFAtypical presentation of PJP: hypercalcemia and kidney injury in an allogeneic stem cell transplant recipient.
BMC Infect Dis
October 2024
Department of Hematology, School of Medicine, Istanbul Medipol University, Istanbul, Türkiye.
Article Synopsis
- Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection that primarily affects immunocompromised individuals, presenting with symptoms like cough, fever, and especially aggressive courses in patients who have undergone allogeneic stem cell transplants.
- A case study details a 56-year-old male who, after an allogeneic stem cell transplant for acute myeloid leukemia, developed hypercalcemia and renal failure along with fatigue, leading to a confirmed diagnosis of PJP.
- Treatment included hydration, furosemide, and denosumab, and ultimately resolved both the hypercalcemia and the PJP infection with the patients’ follow-up showing improvement in symptoms.*
Hyperparathyroidism in patients with low bone mineral density treated with zoledronic acid or denosumab.
Med Clin (Barc)
December 2024
Servicio de Reumatología, Hospital Universitario y Politécnico La Fe, Valencia, España.
Objective: To analyze the prevalence of hyperparathyroidism in patients treated with zoledronic acid (ZA) or denosumab, its relationship with other parameters and how it affects on bone mineral density (BMD) evolution.
Methods: Retrospective observational study in patients with osteoporosis or osteopenia and high risk of fracture, who have received denosumab or ZA for at least two years. Patients diagnosed with hyperparathyroidism or glomerular filtration rate <30ml/min at baseline visit were excluded from the study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!